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ABSTRACT
OBJECTIVE
To determine whether risk adapted intraoperative 
radiotherapy, delivered as a single dose during 
lumpectomy, can effectively replace postoperative 
whole breast external beam radiotherapy for early 
breast cancer.
DESIGN
Prospective, open label, randomised controlled 
clinical trial.
SETTING
32 centres in 10 countries in the United Kingdom, 
Europe, Australia, the United States, and Canada.
PARTICIPANTS
2298 women aged 45 years and older with invasive 
ductal carcinoma up to 3.5 cm in size, cN0-N1, 
eligible for breast conservation and randomised 
before lumpectomy (1:1 ratio, blocks stratified by 
centre) to either risk adapted targeted intraoperative 
radiotherapy (TARGIT-IORT) or external beam 
radiotherapy (EBRT).
INTERVENTIONS
Random allocation was to the EBRT arm, which 
consisted of a standard daily fractionated course 
(three to six weeks) of whole breast radiotherapy, 
or the TARGIT-IORT arm. TARGIT-IORT was given 
immediately after lumpectomy under the same 
anaesthetic and was the only radiotherapy for 
most patients (around 80%). TARGIT-IORT was 
supplemented by EBRT when postoperative 
histopathology found unsuspected higher risk factors 
(around 20% of patients).
MAIN OUTCOME MEASURES
Non-inferiority with a margin of 2.5% for the absolute 
difference between the five year local recurrence rates 
of the two arms, and long term survival outcomes.
RESULTS
Between 24 March 2000 and 25 June 2012, 1140 
patients were randomised to TARGIT-IORT and 1158 
to EBRT. TARGIT-IORT was non-inferior to EBRT: the 
local recurrence risk at five year complete follow-up 
was 2.11% for TARGIT-IORT compared with 0.95% 
for EBRT (difference 1.16%, 90% confidence interval 
0.32 to 1.99). In the first five years, 13 additional 
local recurrences were reported (24/1140 v 11/1158) 
but 14 fewer deaths (42/1140 v 56/1158) for 
TARGIT-IORT compared with EBRT. With long term 
follow-up (median 8.6 years, maximum 18.90 years, 
interquartile range 7.0-10.6) no statistically significant 
difference was found for local recurrence-free survival 
(hazard ratio 1.13, 95% confidence interval 0.91 to 
1.41, P=0.28), mastectomy-free survival (0.96, 0.78 
to 1.19, P=0.74), distant disease-free survival (0.88, 
0.69 to 1.12, P=0.30), overall survival (0.82, 0.63 to 
1.05, P=0.13), and breast cancer mortality (1.12, 0.78 
to 1.60, P=0.54). Mortality from other causes was 
significantly lower (0.59, 0.40 to 0.86, P=0.005).
CONCLUSION
For patients with early breast cancer who met our 
trial selection criteria, risk adapted immediate 
single dose TARGIT-IORT during lumpectomy was an 
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WHAT IS ALREADY KNOWN ON THIS TOPIC
When early breast cancer is treated with breast conserving surgery (lumpectomy) 
rather than mastectomy, adjuvant whole breast postoperative external beam 
radiotherapy, given as multiple doses over several days, reduces the risk of local 
recurrence
Restricting radiotherapy to only the area around the tumour by using 
intraoperative radiotherapy has the benefits of precision and immediacy, and 
avoids the inevitable delay in starting postoperative radiotherapy
Early results of using single dose targeted intraoperative radiotherapy (TARGIT-
IORT) during lumpectomy indicate this approach has many advantages for the 
patient, such as less travelling for treatment, improved quality of life, and fewer 
side effects
WHAT THIS STUDY ADDS
The results of the TARGIT-A trial show that TARGIT-IORT has similar long term local 
control and cancer survival outcomes to whole breast radiotherapy
Mortality from other causes was lower in the TARGIT-IORT arm
Single dose TARGIT-IORT during lumpectomy should be accessible to healthcare 
providers and discussed with patients when surgery for breast cancer is being 
planned
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effective alternative to EBRT, with comparable long 
term efficacy for cancer control and lower non-breast 
cancer mortality. TARGIT-IORT should be discussed 
with eligible patients when breast conserving surgery 
is planned.
TRIAL REGISTRATION
ISRCTN34086741, NCT00983684.
Introduction
In 2018, two million patients were diagnosed as having 
breast cancer worldwide and 626 000 patients died 
from the disease.1 Treatment with breast conserving 
surgery and adjuvant radiotherapy rather than total 
mastectomy is suitable for most patients. Most local 
recurrences occur close to the primary tumour site 
despite the frequent presence of microscopic cancer 
foci in other quadrants.2 3 Based on the hypothesis 
that adjuvant radiotherapy for women with early 
breast cancer could be limited to the tumour bed and 
given immediately during breast conserving surgery 
(lumpectomy), we developed the concept of targeted 
intraoperative radiotherapy (TARGIT-IORT).4-7 When 
the TARGIT-A trial protocol was published in 1999,8 
restricting radiotherapy to only the area around the 
tumour had been explored in small patient series9 and 
one randomised trial,10 which had reported inferior 
results. At that time whole breast radiotherapy was the 
standard of care, and it remains so today, despite the 
publication of our initial results11-13 and several other 
approaches.14-21
TARGIT-IORT provides a well positioned and rapid 
form of tumour bed irradiation focused on the target 
tissues alone, while sparing normal tissues and organs 
such as heart, lung, skin, and chest wall structures.22 
We designed the TARGIT-A randomised trial to compare 
risk adapted TARGIT-IORT with conventional whole 
breast external beam radiotherapy (EBRT) over several 
weeks.4 11 13 The study received ethics approval from 
the Joint University College London and University 
College London Hospital committees of ethics of 
human research. Recruitment began in March 2000 
and was completed in June 2012.
In 2004, four years after recruitment began for 
the main TARGIT-A trial and at the request of centres 
with potentially high numbers of patients, we sought 
additional ethics approval and opened a parallel 
study. This study was previously referred to as the 
post-pathology stratum and recruited 1153 patients 
by using a separate randomisation table. These 
patients were randomised after their initial surgery 
to have either conventional fractionated whole breast 
radiotherapy (n=572) or a further operation to deliver 
delayed radiotherapy to the wound by reopening the 
original incision (n=581). The trial was initiated mainly 
because of easier scheduling of delayed TARGIT-IORT in 
operating theatres. This delayed radiotherapy was not 
intraoperative radiotherapy given during the cancer 
operation; treatment was performed a median of 37 
days after the first excision. The 2013 analysis found 
that this delayed second procedure crossed the 2.5% 
margin of non-inferiority. Therefore, we recommended 
that immediate TARGIT-IORT should be the preferred 
treatment over delayed TARGIT-IORT,13 and delayed 
treatment was no longer used. As specified in the 
statistical analysis plan, which was signed off before 
unblinding for this analysis, we have addressed the 
long term outcomes for this parallel trial in a separate 
paper. 
This paper reports the findings of the TARGIT-A 
trial, in which 2298 patients were randomised after 
their needle biopsy and before any surgical excision 
of the cancer to receive either risk adapted TARGIT-
IORT delivered during the initial excision of cancer or 
postoperative whole breast external beam radiotherapy 
(EBRT). We investigated whether immediate TARGIT-
IORT was non-inferior to EBRT at five year complete 
follow-up in terms of local recurrence, and also 
compared their long term survival outcomes.
Methods
TARGIT-A was a pragmatic, prospective, international, 
multicentre, open label, randomised, phase III trial 
that compared risk adapted TARGIT-IORT with the 
conventional treatment of whole breast EBRT. The 
trial protocol (https://njl-admin.nihr.ac.uk/document/
download/2006598), including details of sample size 
calculations and the random allocation process, has 
been previously described.11 13 In brief, women with 
early breast cancer were eligible if they were aged 45 
years or older, diagnosed by needle biopsy, and suitable 
for wide local excision of invasive ductal carcinoma 
that was unifocal on conventional examination and 
imaging (cT1 and small cT2 ≤3.5 cm, cN0-N1, M0, as 
confirmed by cytology or histology). Breast magnetic 
resonance imaging was not required and only 5.6% of 
patients in the trial had a scan.
Eligible patients were randomly assigned before 
their surgery (in a 1:1 ratio) to receive either a risk 
adapted approach that used single dose TARGIT-IORT 
or EBRT according to standard schedules over several 
weeks, with randomisation blocks stratified by centre. 
The randomisation schedules were generated centrally 
by computer (securely kept in trial centres in Perth 
for Australian centres and London, United Kingdom, 
for all other centres). Requests for randomisation 
were through telephone or fax to the trial office 
(Perth or London), where a trained member of staff 
checked patient eligibility. Treatment was allocated 
from a preprinted randomisation schedule available 
to authorised staff only. Written confirmation of 
randomisation was sent by fax to the site.
All patients gave written informed consent and 
needed to be available for regular follow-up for at 
least 10 years. Follow-up clinical examination was at 
least six monthly for the first five years and annually 
thereafter, including a mammogram once a year.
The experimental arm was risk adapted radiotherapy. 
If the final pathology report showed prespecified 
unpredicted features, EBRT was recommended in 
addition to TARGIT-IORT, with TARGIT-IORT (already 
received during surgery) serving as the tumour bed 
boost. In the core protocol, EBRT was recommended 
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to supplement TARGIT-IORT within the experimental 
arm if the tumour-free margin was less than 1 mm, if 
there was an extensive in situ component (>25%), or 
if unexpected invasive lobular carcinoma was found in 
the postoperative final microscopic histopathological 
examination of the primary tumour excision. 
Additionally, individual centres prespecified any 
other final postoperative histopathology criteria (such 
as grade 3 tumour, node positivity, lymphovascular 
invasion) that would prompt supplemental EBRT to 
be recommended. These criteria were recorded in the 
centre’s treatment policy document before their trial 
recruitment started.
The trial was a comparison of two policies: 
whole breast radiotherapy without selection versus 
individualised risk adapted radiotherapy; a proportion 
of patients who received TARGIT-IORT were also given 
supplemental EBRT by using prespecified criteria. 
These patients were not crossovers, but were offered 
individualised risk adapted radiotherapy according to 
the experimental treatment policy, which was designed 
to reflect the real world scenario.
The TARGIT-IORT technique using the Intrabeam 
device (Carl Zeiss Meditec, Oberkochen, Germany)5-7 
enables a patient to potentially receive all the required 
radiation in a single treatment under the same 
anaesthetic as the primary surgery (efig 1).5-7 23-26 
Radiation is delivered from a point source of 50 kV 
energy x rays at the centre of a spherical applicator 
over 20-50 minutes. The appropriately sized (1.5-5 
cm diameter) applicator is surgically positioned in 
the tumour bed so that breast tissues at risk of local 
recurrence receive the prescribed dose while skin and 
other organs are protected. The surface of the tumour 
bed typically receives 20 Gy that attenuates to 5-7 Gy 
at 1 cm depth. Further details and a video are available 
online (www.targit.org.uk; https://goo.gl/iuF9ZR). The 
patients in the conventional arm underwent standard 
EBRT which always included fractionated whole breast 
radiotherapy for three to six weeks, with or without an 
EBRT tumour bed boost, as determined by local criteria 
prespecified by the collaborating centre.
We designed the trial as a non-inferiority trial. 
Non-inferiority trials in cancer are performed to test 
new treatments that have obvious non-oncological 
advantages, such as better access, convenience, or 
quality of life for the patient, or reduced costs for the 
healthcare system. The non-inferiority statistical test for 
such a comparison is not meant to check for superiority, 
but to assess if the difference is within an acceptable 
margin and the experimental treatment is not 
meaningfully worse than the control. Therefore, whether 
the difference seen between the two randomised arms 
is statistically significant is not relevant here. As long 
as the absolute difference is not clinically significant, 
the new treatment would be deemed non-inferior.27 
Any chosen non-inferiority margin must be one that 
clinicians and patients agree is an acceptable difference 
for the sake of the other benefits. These benefits might 
include lower toxicity, better cosmetic outcome, better 
quality of life, and overall patient preference. Therefore, 
in the original protocol, non-inferiority was specified 
as being achieved if the difference in the binomial 
proportions of local recurrence rate at five years did 
not cross a stringent margin of 2.5% in absolute terms; 
that is, local recurrence risk with TARGIT-IORT minus 
local recurrence risk with EBRT should not be more 
than 0.025 (2.5%). In the 2013 analysis, an even more 
rigorous criterion was used, specifying that the upper 
90% confidence interval of the absolute difference 
must not exceed 0.025 (2.5%).
The 2.5% non-inferiority margin in the TARGIT-A 
trial is a relevant, relatively stringent margin. Patient 
preference studies in the United States, Australia, and 
Europe suggest that 2.5% is an acceptable margin.28-30 
Importantly, it is widely regarded as a safe margin 
because it is well established that a local recurrence 
difference of less than 10% at five years does not 
worsen breast cancer survival31; that is, when the 
risk in arm A minus the risk in arm B is less than 0.1 
(10%). A large increase in local recurrences (>10% at 
five years) is required to lead to increased mortality 
because they can be effectively treated. For example, 
a 20% increase in local recurrence (a risk increase by 
0.2) would cause a 5% increase in deaths (a mortality 
risk increase by 0.05)31; this was the basis for the 
ethics approval of this trial. In the ELIOT trial, which 
also investigated intraoperative radiotherapy, the non-
inferiority margin was set at 7%.15 In recently reported 
trials of systemic therapy, the margin of a 3% difference 
in disease-free survival was considered acceptable.32
Analysis of conventional longer term outcomes in 
breast cancer trials needs to include deaths as events 
for two reasons. Firstly, deaths are one of the most 
important clinical outcomes. Secondly, longer follow-
up in an older population with early breast cancer 
means that death becomes much more common than 
local recurrence. Importantly, if toxicity of treatment 
leads to a difference in mortality then it needs to be 
reflected in the results. The statistical analysis plan for 
this long term analysis was signed off by the chair of the 
independent steering committee and an independent 
senior statistician before the unblinded data were sent 
to the trial statistician for the current analysis. The plan 
specified the primary outcome was local recurrence-
free survival. This outcome is consistent with the 
DATECAN33 and STEEP34 guidelines for clinical events 
to be included in the definitions of time-to-event 
end points in randomised clinical trials assessing 
treatments for breast cancer. Local recurrence-free 
survival is clinically meaningful because it measures 
the chance of a patient being alive without local 
recurrence. Therefore, this outcome includes local 
recurrence or death as events; that is, patients who 
had died were not censored. Clinicians and patients 
need to know the chance of being alive without a 
local recurrence, which is given by local recurrence-
free survival. The other important outcomes were 
invasive local recurrence-free survival, mastectomy-
free survival, distant disease-free survival, overall 
survival, breast cancer mortality, and non-breast 
cancer mortality.
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We performed statistical analysis by using 
established methods.27 35 36 Hazard ratios were 
calculated by using the Cox proportional hazard 
model with TARGIT-IORT as the numerator. We carried 
out censoring appropriately for each outcome; for 
example, for survival outcomes, patients were censored 
at the time of last follow-up, or the date of withdrawal. 
Kaplan-Meier graphs for these long term outcomes 
were presented according to Pocock and colleagues,37 
who recommended that the x axis should be extended 
until 10-20% of patients are at risk of an event. This 
approach also ensures that any long term trends 
(positive or negative) are not missed. We used the 
log rank test to compare differences between survival 
functions and to obtain P values. All analyses were by 
intention to treat according to the randomisation arm.
Each centre specified the cause of death. If the cause 
of death was specified as a non-breast cancer event 
and no distant disease was recorded, it was defined as 
a non-breast cancer death. If the death was recorded 
by the centre to be related to breast cancer, or as per 
convention, if breast cancer was present at the time 
of death, or if the cause of death was recorded as 
unknown or uncertain, it was presumed to be a breast 
cancer death.
The reference date for completeness was 2 May 2018, 
eight years after the first data lock. We considered 
patients to have complete follow-up if they were seen 
for the specified duration of follow-up, if they were 
seen within one year of the reference date, if they had 
died, or if they had withdrawn from the trial. Because 
the last patient was randomised in 2012, the statistical 
analysis plan specified that the five year follow-up 
would be considered complete if 95% of patients had 
complete follow-up. The plan also specified that a 10 
year follow-up would be considered complete if the 
patient had at least 10 years of follow-up, had been seen 
within one year of the reference date, or had died or 
withdrawn from the study; the 10 year follow-up would 
be considered complete if this was achieved by 90% of 
patients. The interim analysis confirmed the safety of 
TARGIT-IORT, but the follow-up was relatively short. 
Therefore, the independent data monitoring committee 
recommended that we continue recruitment while 
accruing the required follow-up. There was no specific 
trial funding for individual centres and so return of 
follow-up relied on individual investigators and the 
efforts of their teams, enthused by the trial centre team. 
The trial statistician and the chief investigator produced 
reports of completeness of follow-up by using blinded 
databases on a regular basis.
Once the thresholds set in the statistical analysis 
plan were reached, the database was unblinded for 
analysis. The reference date for analysis was 3 July 
2019, so that all events up until 2 July 2019 were 
included for analysis. We used Stata version 16.0 for 
data compilation, validation, and analysis. The trial 
steering and data monitoring committees each included 
a patient advocate as a member. Since the last analysis, 
the trial oversight has been provided by an independent 
steering committee, appointed by the Health Technology 
Assessment (HTA) programme of the National Institute 
of Health Research, Department of Health and Social 
Care, UK, which also includes a patient as a member.
Patient and public involvement
Patients have been involved as members of the steering 
committee from the start. Patients were not involved in 
the initial design of the study in 1999-2000, but they 
were involved from the time the trial started. However, 
it was the serious concern about patients’ welfare that 
inspired the study design. The pragmatic nature of this 
trial was designed to suit the patient’s perspective. 
The non-inferiority margin has been validated with 
patient preference studies,28-30 which included asking 
patients about their priorities. Patients were involved 
in recruitment to and conduct of the study as members 
of the steering committee and on several occasions as 
commentators in the national press, TV, and radio. 
Patients assessed the burden of intervention and the 
time required to participate. Unlike most other studies, 
participating in the trial was the main pathway through 
which patients could access TARGIT-IORT and reduce 
the burden of treatment (that is, they were likely to 
avoid external beam radiotherapy) in the 50% of the 
group randomised to receive the TARGIT-IORT arm 
rather than the EBRT arm. A patient has been involved 
during the development of the statistical analysis 
plan, interpretation of the results and writing of the 
manuscript, and is an author of the paper.
Results
Between 24 March 2000 and 25 June 2012, 2298 
patients were recruited to the study: 1140 patients 
were randomised to receive risk adapted immediate 
TARGIT-IORT during lumpectomy and 1158 patients 
were randomised to receive EBRT. Table 1 presents 
patient and tumour characteristics, which were well 
matched between the randomised arms.
Complete follow-up to the prespecified level of 
95% at five years was achieved by mid-2019. Figure 
1 presents the flow and CONSORT (consolidated 
standards of reporting trials) diagrams. Figure 2 shows 
the completeness of follow-up and illustrates that the 
observed follow-up is close to the expected follow-up 
in each arm of the trial. The follow-up duration of the 
two arms did not differ (log rank P=0.22).
For the protocol specified primary outcome of non-
inferiority at five years, we found that immediate 
TARGIT-IORT was non-inferior to EBRT for local 
control (table 2): at five year complete follow-up, the 
number of local recurrences was 24 (including six 
ductal carcinoma in situ) of 1140 (2.11%) for TARGIT-
IORT versus 11 (including one ductal carcinoma in 
situ) of 1158 (0.95%) for EBRT. The difference in local 
recurrence rate was 0.0116 (1.16%) and the 90% 
confidence interval was 0.0032 to 0.0199 (0.32% to 
1.99%), establishing non-inferiority. Testing for non-
inferiority by using five year Kaplan-Meier estimates 
also confirmed that immediate TARGIT-IORT is non-
inferior to EBRT (difference 1.21%, 90% confidence 
interval 0.47% to 1.95%). We also confirmed non-
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inferiority when 95% confidence intervals were used, 
and when per protocol analysis was performed with 
90% and 95% confidence intervals. The number of 
deaths was 42 of 1140 for TARGIT-IORT versus 56 of 
1158 for EBRT.
With long term follow-up (median 8.6 years, 
maximum 18.9 years, interquartile range 7.0-10.6), 
no statistically significant difference was found 
between immediate TARGIT-IORT and EBRT for the 
following outcomes: local recurrence-free survival 
(167 v 147 events, hazard ratio 1.13, 95% confidence 
interval 0.91 to 1.41, P=0.28), invasive local 
recurrence-free survival (154 v 146 events, 1.04, 0.83 
to 1.31, P=0.70), mastectomy-free survival (170 v 175 
events, 0.96, 0.78 to 1.19, P=0.74), distant disease-
free survival (133 v 148 events, 0.88, 0.69 to 1.12, 
P=0.30), overall survival (110 v 131 events, 0.82, 0.63 
to 1.05, P=0.13), and breast cancer mortality (65 v 57 
events, 1.12, 0.78 to 1.60, P=0.54). Mortality from 
other causes was significantly lower (45 v 74 events, 
0.59, 0.40 to 0.86, P=0.005). Analysis according to 
treatment received found that local recurrence-free 
survival was no different from EBRT for the following 
comparisons: TARGIT-IORT plus EBRT (n=241) versus 
EBRT (n=1065): hazard ratio 1.25, 95% confidence 
interval 0.87 to 1.80, P=0.24; and TARGIT-IORT alone 
(n=786) versus EBRT (n=1065): 1.22, 0.95 to 1.57, 
P=0.11. We used Schoenfeld residuals to confirm 
that the proportionality assumption was not violated 
(P=0.87 for local recurrence-free survival and P=0.81 
for mortality). We also confirmed that there was 
no heterogeneity between countries (efig 2). The 
number of patients who died with uncontrolled local 
recurrence at the time of death was similar in the 
two arms of the trial (4/1140 for TARGIT-IORT and 
5/1158 for EBRT, P=0.76). Table 3 gives the number 
of events and absolute event rates for local recurrence 
and mortality up to five years, and beyond five years. 
Figure 3 shows the Kaplan-Meier curves and figure 4 
shows magnified Kaplan-Meier curves. Table 4 gives 
the causes of death.
Discussion
We based the TARGIT-IORT approach on the clinical 
observation that local recurrence after breast 
conserving surgery, with or without whole breast 
irradiation, occurs predominantly within the index 
quadrant.23 This observation holds true despite the 
fact that more than 60% of patients for whom breast 
conservation is a treatment have foci of the disease 
outside the index quadrant.23 38 Using this observation 
that most local recurrences occur in the index quadrant 
as the rationale for partial breast irradiation has also 
been reiterated by subsequent investigators.15 17 19 The 
propensity of tumour recurrence in the index quadrant 
could be owing to a tumour promoting effect of the 
microenvironment of the surgical wound,39-41 a risk 
that seems to be favourably influenced by TARGIT-
IORT to the fresh tumour bed.39 41 42
Early results of using single dose TARGIT-IORT 
during lumpectomy were promising, and the treatment 
Table 1 | Patient and tumour characteristics in the TARGIT-IORT and EBRT arms
Characteristics TARGIT-IORT (n=1140) EBRT (n=1158)
Age (years)
≤50 117 (10.3) 99 (8.6)
51-60 362 (31.8) 375 (32.4)
61-70 481 (42.2) 524 (45.3)
>70 180 (15.8) 160 (13.8)
Body mass index 
Normal (<25) 408 (41.0) 420 (42.2)
Overweight (25-29.9) 375 (37.7) 329 (33.1)
Obese (≥30) 212 (21.3) 246 (23.7)
Unknown 145 (12.7) 163 (14.1)
Specimen weight (g)
Median (interquartile range) 40 (25-65) 40 (24-70)
Pathological tumour size (mm; P=0.70)
≤10 369 (33.1) 370 (33.1)
11-20 571 (51.2) 557 (49.9)
>20 176 (15.8) 190 (17.0)
Unknown 24 (2.1) 41 (3.5)
Grade
1 275 (24.5) 286 (25.6)
2 621 (55.4) 615 (55.0)
3 226 (20.1) 217 (19.4)
Unknown 18 (1.6) 40 (3.5)
Margin
Free 1007 (89.4) 993 (88.2)
Ductal carcinoma in situ only 54 (4.8) 60 (5.3)
Invasive 65 (5.8) 73 (6.5)
Unknown 14 (1.2) 32 (2.8)
Re-excision 76 (6.7) 97 (8.4)
Lymphovascular invasion
Absent 931 (83.4) 946 (84.6)
Present 185 (16.6) 172 (15.4)
Unknown 24 (2.1) 40 (3.5)
Lymph nodes involved
0 872 (77.4) 893 (79.2)
1-3 213 (18.9) 205 (18.2)
>3 41 (3.6) 29 (2.6)
Unknown 14 (1.2) 31 (2.7)
Estrogen receptor status
Positive 1005 (89.8) 1030 (91.7)
Negative 114 (10.2) 93 (8.3)
Unknown 21 (1.8) 35 (3.0)
Progesterone receptor status
Positive 895 (80.3) 921 (82.7)
Negative 220 (19.7) 193 (17.3)
Unknown 25 (2.2) 44 (3.8)
Human epidermal growth factor receptor 2 status
Positive 156 (14.5) 164 (15.1)
Negative 920 (85.5) 925 (84.9)
Unknown 64 (5.6) 69 (6.0)
Method of presentation
Screen detected 739 (67.0) 755 (68.0)
Symptomatic 364 (33.0) 355 (32.0)
Unknown 37 (3.3) 48 (4.2)
Endocrine therapy
Received 897 (81.5) 894 (81.1)
Did not receive 204 (18.5) 209 (18.9)
Unknown 39 (3.4) 55 (4.8)
Chemotherapy
Received 239 (21.7) 218 (19.7)
Did not receive 863 (78.3) 887 (80.3)
Unknown 38 (3.3) 53 (4.6)
EBRT=external beam radiotherapy; TARGIT-IORT=targeted intraoperative radiotherapy.
Data are numbers (percentages). For percentage calculation, the denominator for unknown percentages is the 
total number randomised (1140 and 1158) and the denominator for each category is the total number of known 
patients. No imbalance was found for any of these characteristics between the two randomised arms.
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was found to have advantages for the patient, such 
as convenience, reduced travel and personal costs, 
improved quality of life, and fewer side effects.43-47 
However, the international community has been 
waiting for the long term follow-up outcomes before 
this approach is more widely adopted.
Statement of principal findings
The data presented here confirm that TARGIT-IORT 
is non-inferior to EBRT in terms of local control at 
protocol specified five year complete follow-up (local 
recurrence risk 2.11% for TARGIT-IORT v 0.95% 
for EBRT). Additionally, fewer deaths occurred with 
TARGIT-IORT. When we compared 1140 patients 
treated with TARGIT-IORT with 1158 patients treated 
with EBRT, 13 more local recurrences and 14 fewer 
deaths were reported. Figure 5 shows these raw data 
apportioned to 100 patients.
The Kaplan-Meier curves illustrate the long 
term results up to 12 years. These data confirm the 
comparable effectiveness of TARGIT-IORT versus EBRT 
in terms of cancer control, with no difference in local 
recurrence-free survival, invasive local recurrence-free 
survival, mastectomy-free survival, or distant disease-
Eligibility
Age ≥45 years
Diagnosis established by needle biopsy
Unifocal invasive ductal carcinoma preferably ≤3.5 cm, cN0-N1 (MRI not required)
Breast conserving surgery feasible
Conventional radiotherapy
Standard fractionated whole breast
EBRT over three to six weeks
Randomise
Flow chart outlining TARGIT-A recruitment
CONSORT diagram
Did not receive allocated treatment
Received EBRT†
Did not receive TARGIT-IORT or EBRT
Had a mastectomy
65
10
38
Patients enrolled and randomised before excision of cancer
2298
1158
Risk adapted radiotherapy
TARGIT-IORT focused to tumour bed and delivered
in single dose with Intrabeam during lumpectomy
If high risk factors are found on final
pathology, supplemental EBRT recommended
1140
2298
Allocated to TARGIT-IORT with or without EBRT Allocated to EBRT
11581140
Withdrawn from further follow-up*
Included in analysis
1158
Included in analysis
1140
9
Withdrawn from further follow-up*
28
113
Received allocated treatment‡
Received TARGIT-IORT
Received TARGIT-IORT plus EBRT§
786
241
Did not receive allocated treatment
Received TARGIT-IORT†
Received TARGIT-IORT and EBRT†
Did not receive TARGIT-IORT or EBRT
Did not have any surgery (letrozole
  only)
Had a mastectomy
5
17
29
1
41
93
1027
Received allocated treatment‡
Received EBRT1065
1065
Fig 1 | Flowchart outlining TARGIT-A recruitment and CONSORT (consolidated standards of reporting trials) diagram. 
*Difference in number withdrawn was statistically significant (P=0.002). †Crossovers: 65/1140 (5.7%) allocated 
TARGIT-IORT received EBRT, and 22/1158 (1.9%) allocated EBRT received TARGIT-IORT. ‡1027/1140 (91%) allocated 
TARGIT-IORT and 1065/1158 (92%) allocated EBRT received allocated treatment. §As per protocol, 241/1140 
(21.1%) patients allocated TARGIT-IORT received EBRT after TARGIT-IORT. EBRT=external beam radiotherapy; TARGIT-
IORT=targeted intraoperative radiotherapy
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free survival for at least 12 years from randomisation 
(fig 3).
Breast cancer specific mortality was similar for both 
arms, however far fewer deaths were reported from 
causes other than breast cancer in the TARGIT-IORT 
arm. Even modern radiotherapy increases cardiac and 
lung cancer mortality and the results are consistent 
with our previously published data48-52 and a meta-
analysis of randomised trials.53 54 Furthermore, the 
Kaplan-Meier curve for overall survival for TARGIT-
IORT always remains above EBRT, with the curves 
continuing to separate further well beyond 10 years.
Strengths and weaknesses of the study
The pragmatic trial design is a major strength because 
the experimental arm simulated the potential future 
real world practice. Patients would get TARGIT-IORT 
during their initial cancer operation, and if found to 
have high risk factors, they would receive supplemental 
whole breast radiotherapy, making the results more 
clinically applicable. The international setting and 
broad inclusion criteria mean that the results are 
generalisable across relatively broad eligibility criteria 
and across various continents, even though centres of 
excellence participated in the trial.
Patients were randomised between 2000 and 2012. 
Substantial effort along with close collaboration from 
each centre enabled a high level of completeness of 
long term data. Consequently, another strength of the 
TARGIT-A trial is that it has more long term follow-up 
data than other published trials comparing individual 
techniques of partial breast irradiation with whole 
breast irradiation for invasive breast cancer (table 5, 
fig 6). Additionally, figure 2 shows that actual follow-
up time is close to the follow-up time expected from 
the date patients were recruited, which means that 
substantial unknown data are unlikely. The long 
duration and high level of completeness of follow-up 
mean that the trial outcome is reliable and robust, 
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Fig 2 | Completeness of follow-up. Curves for actual follow-up and how close they are 
to curves for expected follow-up. Expected is presumed equal to actual if patients have 
withdrawn or died. No significant difference in follow-up duration between TARGIT-IORT 
and EBRT (log rank P=0.22). EBRT=external beam radiotherapy; TARGIT-IORT=targeted 
intraoperative radiotherapy
Table 2 | Analysis of non-inferiority by using binomial proportions and Kaplan-Meier estimates
Analysis TARGIT-IORT EBRT
Intention-to-treat analysis (n=1140; n=1158)
Binomial proportions of five year local recurrence (%) 2.11 0.95
Difference (%; 90% CI; 95% CI) 1.16 (0.32 to 1.99; 0.15 to 2.16)
Kaplan-Meier estimates of local recurrence at five year complete follow-up (%; SE) 2.23 (0.45) 1.02 (0.31)
Difference (%; 90% CI; 95% CI) 1.21 (0.47 to 1.95; 0.33 to 2.09)
Per protocol analysis (n=1027; n=1065)
Binomial proportions of five year local recurrence (%) 2.24 0.94
Difference (%; 90% CI; 95% CI) 1.30 (0.40 to 2.20; 0.23 to 2.38)
Kaplan-Meier estimates of local recurrence at five year complete follow-up (%; SE) 2.36 (0.49) 0.99 (0.31)
Difference (%; 90% CI; 95% CI) 1.37 (0.56 to 2.18; 0.41 to 2.33)
EBRT=external beam radiotherapy; SE=standard error; TARGIT-IORT=targeted intraoperative radiotherapy.
The protocol specified that the non-inferiority test should be performed with a prespecified margin of 2.5% at five years. The statistical analysis plan 
stated that analysis of non-inferiority should be performed by calculating difference in binomial proportion of local recurrence rates at five years, and 
that non-inferiority would be considered as established if upper 90% confidence interval of difference did not cross 0.025 (2.5%). Local recurrence risk 
and difference in this risk are depicted as absolute percentage (eg, difference in risk of 0.0116 is depicted as 1.16%). For completeness, test for non-
inferiority was performed by using five year Kaplan-Meier estimates of local recurrence and per protocol analysis. Results show that TARGIT-IORT remains 
non-inferior to EBRT.
Table 3 | Number of events and absolute event rates (percentages) of local recurrence and death
Local recurrence and death
TARGIT-IORT (n=1140) EBRT (n=1158)
≤5 years >5-19 years ≤5 years >5-19 years
Local recurrence was invasive with or without DCIS 15 (1.3) 17 (1.5) 9 (0.8) 10 (0.9)
Local recurrence was only DCIS 6 (0.5) 6 (0.5) 1 (0.1) 0
Local recurrence type was unknown* (assumed as invasive for analysis) 3 (0.3) 13 (1.1) 1 (0.1) 3 (0.3)
No of deaths 42 (3.7) 68 (5.9) 56 (4.8) 75 (6.5)
DCIS=ductal carcinoma in situ; EBRT=external beam radiotherapy; SE=standard error; TARGIT-IORT=targeted intraoperative radiotherapy.
There is complete follow-up at five years and maximum follow-up at 18.9 years. This table gives the number of events up to five years and beyond five 
years. The protocol specified that number of local recurrences (all types) at five years should be used for calculation of non-inferiority at 2.5% margin and 
all types of local recurrences were included.
*Local recurrence of unknown type was included as invasive local recurrence in long term invasive local recurrence-free survival analysis.
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Fig 3 | Kaplan-Meier estimates and curves for the following outcomes for TARGIT-IORT versus EBRT in the TARGIT-A trial: local recurrence-free 
survival, invasive local recurrence-free survival, mastectomy-free survival, distant disease-free survival, breast cancer specific survival, non-breast 
cancer survival, and overall survival. Figures under titles are hazard ratios (95% confidence intervals) and log rank test P values. EBRT=external 
beam radiotherapy; TARGIT-IORT=targeted intraoperative radiotherapy
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and with 2298 participants, this trial is one of the 
largest in the field (table 5, fig 6). The trial was a 
result of an academic insight and was investigator 
initiated and funded by the HTA programme of the 
UK Department of Health and Social Care, rather 
than by industry sponsorship. The investigative team 
was multidisciplinary and consisted of patients and 
experts in surgical oncology, radiation oncology, 
clinical oncology, radiation physics, medical statistics, 
psycho-oncology, health economics, and clinical trial 
management.
The ratio of ductal carcinoma in situ to invasive 
recurrence was higher in the TARGIT-IORT arm (12:32) 
compared with the EBRT arm (1:19; table 3). One 
limitation of this study is that we do not know if this 
finding is owing to overdiagnosis and ascertainment 
bias because of potentially more frequent use of 
mammography in patients randomised to TARGIT-
IORT, or if it is a real effect. However, this increase in 
diagnosis of ductal carcinoma in situ in the TARGIT-
IORT arm did not lead to a reduction in mastectomy-
free survival.
Another limitation of the study was that we did not 
collect all the background risk factors for deaths from 
non-breast cancer causes. However, the major risk 
factors for cardiovascular disease55 and malignant 
disease56 that were formally collected during the trial 
were age and body mass index, and these factors were 
distributed evenly between the two randomised arms. 
While smoking history and other common risk factors 
were not collected, it is unlikely that their incidence 
would be imbalanced in such a large randomised trial. 
Additionally, cause of death could not be determined 
for every patient. Therefore, patients were deemed to 
have died of causes other than breast cancer only if the 
local principal investigator had clearly specified that 
the cause of death was not breast cancer and breast 
cancer was not present, and only when there was no 
record of the patient having had any relapse of breast 
cancer.
The perspective in relation to other studies 
investigating partial breast irradiation
Partial breast irradiation was heralded as a new 
standard12 at the time of the first publication of the 
TARGIT-A trial.11 Several other supporting trials have 
since been published, including the ELIOT trial,15 
and studies examining brachytherapy,18 and partial 
breast EBRT.17 19 The TARGIT-A and ELIOT trials 
differ considerably in their inclusion criteria, and 
most importantly, have entirely different surgical 
and radiotherapeutic techniques, and so are not 
comparable. A Cochrane meta-analysis published in 
201657 included all diverse methods of partial breast 
irradiation, but could not make definitive conclusions 
because of data limitations. Our own meta-analysis 
that only examined mortality (initially published in 
2016 and updated in 2018)53 54 found that partial 
breast irradiation has no impact on breast cancer 
mortality but reduces non-breast cancer mortality and 
overall mortality.
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Fig 4 | Kaplan-Meier curves showing differences in breast cancer mortality, non-breast 
cancer mortality, and overall mortality in TARGIT-A trial for TARGIT-IORT v EBRT. Figures 
under titles are hazard ratios (95% confidence intervals) and log rank test P values. 
EBRT=external beam radiotherapy; TARGIT-IORT=targeted intraoperative radiotherapy
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In general, the other trials of partial breast 
irradiation with EBRT have included patients with 
cancer with considerably better prognosis. For 
example, when we compared the IMPORT-Low trial19 
patient population with that of the TARGIT-A trial, 3% 
versus 22% had node positivity, and 9% versus 20% 
had grade 3 tumours. Furthermore, this new analysis 
of long term data suggests that the greater proportion 
of patients with higher risk disease has not jeopardised 
the outcome in the TARGIT-A trial. We recommend that 
risk adapted TARGIT-IORT should be used in patients 
who would have been eligible for the TARGIT-A trial. 
Partial breast irradiation with EBRT still requires up to 
three weeks of daily radiation with about 16 hospital 
visits.19 Although newer brachytherapy or some 
intensity modulated radiotherapy regimens could be 
completed in 10 fractions over five days, these trials 
had much smaller numbers of patients (102358 and 
23317 patients with five years of follow-up compared 
with 2048 in immediate TARGIT-A v EBRT; table 5, fig 
6). Most of these techniques have adverse physical, 
social, financial,59-61 and environmental impacts,43 
and do not substantially reduce the heavy workload of 
radiotherapy departments. Conversely, TARGIT-IORT 
delivered during the operation enables four fifths of 
patients to avoid visiting the radiotherapy centre at all.
Meaning of the study and implications for clinicians 
and policy makers
The long term results of this trial have shown that 
risk adapted single dose TARGIT-IORT given during 
lumpectomy can effectively replace the mandatory use 
of several weeks of daily postoperative whole breast 
radiotherapy in patients with breast cancer undergoing 
breast conservation. Crucially, 80% of patients 
required no additional radiotherapy after TARGIT-IORT. 
Additionally, TARGIT-IORT reduced non-breast cancer 
mortality. The advantage to the patient of avoiding 
postoperative radiotherapy could be considered 
obvious. Furthermore, formal studies have also been 
performed and have reported quality of life and patient 
reported outcomes such as cosmesis, breast related 
quality of life, and breast pain to be superior with 
TARGIT-IORT in the first five years.44-47 Additionally, 
patients prefer this approach even when faced with a 
potentially higher local recurrence risk.28-30 Moreover, 
80% of patients, many of whom live a considerable 
distance from the radiotherapy centre,43 57 avoid the 
need for daily hospital visits for three to six weeks, 
which would be required for established radiotherapy 
techniques. For such patients, TARGIT-IORT provides 
the opportunity for breast conservation rather than 
being obliged to choose mastectomy.62 Even as recently 
as 2015, in a modern urban community (New Jersey, 
US), patients who lived more than 9.2 miles from the 
radiation facility (or more than 19 minutes away by 
car) compared with less than 9.2 miles away were 36-
44% more likely to receive a mastectomy than breast 
conservation.63
Another important advantage is the major cost 
savings for the health services reported in previously 
published studies of health economics of the TARGIT-A 
trial.59-61 All these factors are important when 
considering a change of policy and determining which 
treatments should be funded at the national level by 
organisations such as the NHS in the UK and Medicare 
or Medicaid in the US. While the payers will save 
scarce healthcare resources by using TARGIT-IORT, the 
providers will also want to use this approach when the 
payment model is changed to be value based rather 
than activity based.
Another important aspect is the well recognised 
phenomenon of overdiagnosis of breast cancer 
because of systematic population screening. This is 
a difficult problem because the potential of reduced 
breast cancer mortality needs to be balanced against 
the definite harms of overtreatment of women who 
might not have had a diagnosis of breast cancer if it 
were not for the screening programme. TARGIT-IORT 
could largely reduce the burden of treatment on such 
patients, and has been recommended by the Marmot 
committee.64
Implications for patients
When these results are expressed from the patient’s 
perspective, without any definitions of non-inferiority, 
they would read as follows: “I understand from your 
explanation that if I choose to have intraoperative 
radiotherapy during my lumpectomy operation, the 
whole treatment will probably be completed in one go. 
I understand that the chance of avoiding a full course 
of traditional whole breast radiotherapy is about 80%, 
which requires several daily visits to complete. The 
results of this study have reassured me that choosing 
intraoperative radiotherapy doesn’t reduce my long 
term chances of survival or keeping my breast, and 
remaining cancer free. You have also told me that there 
will be fewer long term side effects, a better quality of 
life and that the cosmetic result is likely to be better. I 
am also reassured to learn that this treatment does in 
fact reduce my chance of death from causes other than 
breast cancer.”
Patients are entitled to choose which approach is 
right for them, based on effectiveness, convenience, 
Table 4 | Number of deaths from breast cancer and other causes
Causes of death TARGIT-IORT EBRT Total
Death from breast cancer
Breast cancer* 35 32 —
Breast cancer present at time of death* 6 7 —
Unknown or uncertain* 24 18 —
Total breast cancer deaths 65 57 122
Death from other causes*
Other cancers 15 21 —
Cardiovascular causes 8 20 —
Pulmonary causes 4 9 —
Other causes/exact cause not given 18 24 —
Total non-breast cancer deaths 45 74 119
Total 110 131 241
EBRT=external beam radiotherapy; TARGIT-IORT=targeted intraoperative radiotherapy.
*Case record form for death completed by centre stipulated classification of deaths as one of the following: 
breast cancer; breast cancer present at time of death including previously reported distant disease; not breast 
cancer and breast cancer not present; unknown or uncertain. As per convention, only deaths classified as not 
breast cancer and breast cancer not present were classified as non-breast cancer deaths.
 o
n
 26 August 2020 by guest. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.m2836 on 19 August 2020. Downloaded from 
RESEARCH
the bmj | BMJ 2020;370:m2836 | doi: 10.1136/bmj.m2836 11
TARGIT-IORT during lumpectomy
Alive aer local recurrence (n=2)
Alive (n=96)
Lumpectomy and postoperative EBRT
Alive aer local recurrence (n=1)
Alive (n=95)
Had distant relapse (n=3)
Died (n=4)
Had distant relapse (n=3)
Died (n=5)
Fig 5 | Pictogram showing outcomes in TARGIT-A trial of TARGIT-IORT v EBRT for breast cancer. Complete follow-up 
is available for five years. Each dot represents a patient. Absolute numbers of patients who had local recurrences, 
distant disease, and died (TARGIT-IORT: 24/1140 local recurrences, 34/1140 distant disease, and 42/1140 deaths; 
EBRT: 11/1158 local recurrences, 31 distant disease, and 56/1158 deaths) are apportioned per 100 patients for 
each treatment type. At five years, one more local recurrence and one less death were reported per 100 patients. 
EBRT=external beam radiotherapy; TARGIT-IORT=targeted intraoperative radiotherapy
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personal cost, quality of life, and side effects. To allow 
a truly informed patient to make the choice between 
a risk adapted TARGIT-IORT policy and conventional 
EBRT, we need to supply the data using absolute 
numbers in an easily accessible and comprehensible 
way.65 A pictographic display (fig 5), based on the raw 
numerical data, is a transparent and accurate way of 
supporting the patient to make an informed choice.
We believe that the long term data presented in this 
paper, together with many benefits for the patient, 
provide compelling evidence in favour of TARGIT-
IORT as an effective alternative for this large group of 
patients with early breast cancer who are suitable for 
breast conservation. Ultimately the treatment patients 
receive should be their choice and they should be 
provided with the data in a format which is transparent, 
straightforward, and easily understood.
Future and ongoing work
Additional work based on these results includes 
subgroup analysis, an analysis of local recurrence as 
a hazard for distant disease, and an analysis exploring 
the mechanisms behind the differences in non-breast 
cancer mortality seen in the trial. We will also present 
a web based tool to allow clinicians to use the risk 
adapted approach. The inputs for this tool include 
individual patient data, and the output gives the 
probability of a patient needing supplemental EBRT 
after TARGIT-IORT within the TARGIT-A trial. Further 
investigation into the nature of local recurrences will 
Table 5 | Number of patients at risk at various time points in published randomised trials that use different techniques 
of partial breast irradiation for invasive breast cancer
Study Total
No of patients at risk*
5 years 6 years 7 years 8 years 9 years 10 years 11 years 12 years
TARGIT-A (immediate TARGIT-IORT) 2298 2048 1967 1736 1361 1035 749 587 295
TARGIT-A (delayed TARGIT-IORT) 1153 1097 1068 967 781 582 364 227 146
ELIOT (IORt)15 1305 — 676 — 305 — 29 — —
Florence (IMRT; 5 days daily doses)17 465 233 — — — — — —
GEC-ESTRO (2×5 days brachytherapy)18 1120 1023 784 — — — — — —
IMPORT-Low (3 weeks EBRT)19 1343 1119 661 239 — — — — —
Budapest (7 days brachytherapy)16 258 — 231 — 113 — 134 — 57
NSABP-B39 3DCRT/IMRT (10# 8 days†)20 2193 — 1915 — 1335 — 930 — —
NSABP-B39 Balloon (10# 8 days†)20 811 — 708 — 494 — 344 — —
RAPID 3DCRT/IMRT (10# 8 days†)21 1754 1593 1548 1344 986 654 — — —
Leeds (EBRT 28 days)14 174 130 120 106 88 64 40 27 16
Christie (EBRT 10 days)10 708 400 250 127 40 — — — —
10# 8 days=10 fractions in eight days; EBRT=external beam radiotherapy; IMRT=intensity modulated radiotherapy; IORT=intraoperative radiotherapy; 
TARGIT-IORT=targeted intraoperative radiotherapy.
Values are shown graphically in figure 6. Proportion of invasive cancer: 100% for TARGIT-A, ELIOT, IMPORT-Low, Budapest, Leeds, and Christie, 73% for 
NSABP-B39, 82% for RAPID, 89% for Florence, and 95% for GEC-ESTRO.
*Follow-up durations shown in Kaplan-Meier plots.
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Fig 6 | Amount of data in randomised trials of different techniques of partial breast irradiation for invasive breast cancer. 10# 8 days=10 fractions in 
eight days; EBRT=external beam radiotherapy; IMRT=intensity modulated radiotherapy; IORT=intraoperative radiotherapy; TARGIT-IORT=targeted 
intraoperative radiotherapy
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include molecular markers and the location within the 
breast.
In the extended follow-up of the TARGIT-A trial 
(TARGIT-Ex; funded by the HTA programme of the 
National Institute for Health Research, Department of 
Health and Social Care in the UK, HTA 14/49/13) we 
will use new methods such as direct patient contact 
and linkage with the Office for National Statistics. 
We are also currently inviting women who would fall 
outside the eligibility criteria of the TARGIT-A trial 
to participate in the TARGIT-B(oost) trial (funded 
by HTA 10/104/07), already opened in 36 centres 
internationally, which is comparing TARGIT-IORT as a 
tumour bed boost with EBRT boost in younger women 
or women who have higher risk disease to test for 
superiority in terms of local control and survival.
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